Proxima Health provides a clinical‑grade blood test that quantifies 18 environmental toxins—including heavy metals, PFAS, microplastics, and pesticides—and pairs the results with evidence‑based lifestyle protocols to lower exposure. For individuals with elevated toxin burdens, the company offers Inuspheresis, an advanced therapeutic apheresis procedure that filters toxins from the bloodstream. This integrated diagnostic, preventive, and interventional model enables patients and clinicians to identify hidden exposures and take targeted action to improve health.
Funding
Funding not disclosed
Founders
Product
Problem
Many individuals are unknowingly exposed to a wide range of environmental toxins—including heavy metals, PFAS “forever chemicals,” microplastics, pesticides, and endocrine disruptors—yet standard medical testing does not routinely measure these contaminants in blood or urine. Without precise exposure data, people cannot take targeted actions to reduce or eliminate harmful substances, leading to increased risk of chronic disease and reduced longevity.
Solution
Proxima Health offers a three‑step approach to address hidden toxin exposure. First, the Proxima Health Baseline test quantifies 18 specific environmental toxins in a blood sample with clinical precision, providing a clear picture of an individual’s current burden. Second, evidence‑based lifestyle protocols are delivered to help users lower ongoing exposure and support natural detoxification pathways. Finally, the company provides Inuspheresis, an advanced therapeutic apheresis (blood filtration) procedure that physically removes accumulated toxins from the bloodstream, facilitating recovery and reducing toxin‑related health risks. The integrated diagnostic, preventive, and interventional model enables patients and clinicians to move from uncertainty to actionable treatment.
Target Audience
Primary customers are health‑conscious individuals and patients with chronic or toxin‑related conditions, as well as physicians, integrative medicine clinics, and wellness practitioners seeking precise exposure data and therapeutic apheresis options.
Features
- Blood test measuring 18 toxin markers, including heavy metals (lead, mercury), PFAS (PFOS, PFOA, PFHxS), microplastics, endocrine disruptors (BPA, MEHP), pesticides (glyphosate, DDT), solvents (benzene), pollutants (PCB‑156, PBDE‑47), mold toxin (ochratoxin A) and persistent pathogens (Borrelia, COVID spike protein)
- Clinical‑grade laboratory analysis delivering quantitative results for each toxin class
- Personalized, evidence‑based lifestyle recommendations to reduce exposure and support natural detox pathways
- Inuspheresis therapeutic apheresis, a double‑filtration blood purification protocol developed in Europe and adapted for U.S. use
- Proven efficacy supported by peer‑reviewed studies linking apheresis to reductions in autoantibodies, inflammation, lipid abnormalities, and toxin levels
- Practitioner partnership program enabling clinicians to integrate testing and apheresis into their practice
- Secure, cloud‑based reporting portal for patients and providers to view results, track trends, and coordinate follow‑up care